Protective Effects of Herbacetin in Experimental Colitis: Targeting NF-κB and NLRP3 Pathways

Area of Science:

• Pharmacology and Toxicology
• Gastroenterology
• Immunology

Background:

• Ulcerative colitis (UC), a form of inflammatory bowel disease (IBD), involves immune system dysregulation.
• Herbacetin, a natural flavonoid, exhibits anti-inflammatory properties, but its efficacy in experimental colitis remains uninvestigated.

Purpose of the Study:

• To evaluate the therapeutic potential of herbacetin in a mouse model of TNBS-induced colitis.
• To investigate the anti-inflammatory mechanisms of herbacetin, including its effects on inflammatory markers and gene expression.

Main Methods:

• Colitis was induced in BALB/c mice using 2,4,6-trinitrobenzenesulfonic acid (TNBS).
• Mice were treated orally with varying doses of herbacetin or sulfasalazine for seven days.
• Disease activity index (DAI), colon length, histopathology, myeloperoxidase (MPO), nitric oxide (NO) levels, and inflammatory gene expression (NF-κB, iNOS, COX-2, NLRP3, IL-1β, IL-18) were assessed.

Main Results:

• Herbacetin significantly ameliorated weight loss and reduced DAI in TNBS-induced colitis mice in a dose-dependent manner.
• Treatment with herbacetin counteracted the reduction in colon length and increase in weight/length ratio caused by TNBS.
• Herbacetin suppressed mucosal injury, inflammatory infiltration, MPO and NO levels, and downregulated the expression of key inflammatory genes (NF-κB, iNOS, COX-2, NLRP3, IL-1β, IL-18).

Conclusions:

• Herbacetin demonstrates significant protective effects against experimental colitis.
• Its therapeutic action involves suppressing neutrophil infiltration, oxidative stress, and NF-κB-NLRP3-mediated inflammatory pathways.
• Herbacetin shows promise as a potential therapeutic agent for ulcerative colitis and related inflammatory bowel diseases.